Clinical Trial Update: Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial updating immunotherapy with nivolumab plus lenvatinib for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED